Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KYTX | Common Stock | Conversion of derivative security | +3.79M | 3.79M | Feb 12, 2024 | See Footnote | F1, F2 | |||
transaction | KYTX | Common Stock | Conversion of derivative security | +736K | 736K | Feb 12, 2024 | See Footnote | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KYTX | Series A-1 Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -4.4M | -100% | $0.00* | 0 | Feb 12, 2024 | Common Stock | 967K | See Footnote | F2, F4 | |
transaction | KYTX | Series A-2 Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -8.83M | -100% | $0.00* | 0 | Feb 12, 2024 | Common Stock | 1.94M | See Footnote | F2, F4 | |
transaction | KYTX | Series B Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -4.01M | -100% | $0.00* | 0 | Feb 12, 2024 | Common Stock | 880K | See Footnote | F2, F4 | |
transaction | KYTX | Series B Redeemable Convertible Preferred Stock | Conversion of derivative security | $0 | -3.35M | -100% | $0.00* | 0 | Feb 12, 2024 | Common Stock | 736K | See Footnote | F3, F4 |
Id | Content |
---|---|
F1 | Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. |
F2 | Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
F3 | Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. |
F4 | The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. |